Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM.
Published In/Presented At
Tai, W., Wahab, A., Franco, D., Shah, Z., Ashraf, A., Abid, Q. U., Mohammed, Y. N., Lal, D., & Anwer, F. (2022). Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. Antibodies (Basel, Switzerland), 11(2), 22. https://doi.org/10.3390/antib11020022
Medicine and Health Sciences
Department of Medicine, Hematology-Medical Oncology Division Fellows and Residents, Fellows and Residents